The landmark approval of adult stem cell research at the CCMI and the availability of funding make Ireland an attractive location for ground-breaking research and clinical trials using adult stem cells. Ireland has broken new ground in the field of adult stem cell research in recent months.
The Health (Pricing and Supply of Medical Goods) Act 2013 was recently signed into law. The act puts in place the foundations for pharmacists to substitute a cheaper generic medicine when a more expensive branded medicine has been prescribed. However, it will have no effect in the marketplace until the Irish Medicines Board has published its list of interchangeable medicines.
The EU Falsified Medicines Directive is yet to be transposed into Irish law. However, the Irish Medicines Board has issued guidance on the registration requirements for manufacturers, importers, distributors and brokers of active substances. All entities in the supply chain should consider the impact that the new regime will have on their existing contracts and implement any necessary changes.
Ireland, in common with many other jurisdictions, has experienced a significant level of debate and controversy regarding the prices of drugs supplied under state-sponsored community drugs schemes. Recent initiatives aim to drive down the state's medicines bill, including a new medicines supply agreement which is predicted to provide €400 million in savings.